BIG
ENTA icon

Brooklyn Investment Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Brooklyn Investment Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,153
Closed -$324K – 1518
2025
Q3 		$324K Buy
43,153
+639
+2% +$5.11K 0.04% 397
2025
Q2 		$321K Buy
+42,514
New +$256K 0.04% 414

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Brooklyn Investment Group's ENTA Position: Q4 2025 in Review

Brooklyn Investment Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 43,153 shares — an estimated $324K sold.

Brooklyn Investment Group first reported a position in ENTA in Q2 2025 and held it in 2 quarters. The position peaked at $324K in Q3 2025. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Brooklyn Investment Group reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 43,153 Enanta Pharmaceuticals shares in Q4 2025, an estimated $324K.
  • Brooklyn Investment Group first reported a position in Enanta Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Brooklyn Investment Group's Enanta Pharmaceuticals position peaked at $324K in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Brooklyn Investment Group's 13F filing for Q4 2025, filed 12 Feb 2026.